Research advances in chimeric antigen receptor-modified T-cell therapy (Review)
- Authors:
- Yuxi Luo
- Guiqin Song
- Shichu Liang
- Feifei Li
- Kang Liu
-
Affiliations: Institute of Tissue Engineering and Stem Cells, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Biology, North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, The First Clinic of Anhui Medical University, Hefei, Anhui 230032, P.R. China, Department of Pathophysiology, Anhui Medical University, Hefei, Anhui 230032, P.R. China - Published online on: March 16, 2021 https://doi.org/10.3892/etm.2021.9915
- Article Number: 484
-
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Panagopoulou TI and Rafiq QA: CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering. Biotechnol Adv. 37(107411)2019.PubMed/NCBI View Article : Google Scholar | |
|
Couzin-Frankel J: Breakthrough of the year 2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Tan S, Li D and Zhu X: Cancer immunotherapy: Pros, cons and beyond. Biomed Pharmacother. 124(109821)2020.PubMed/NCBI View Article : Google Scholar | |
|
Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, et al: Neoantigen vaccine: An emerging tumor immunotherapy. Mol Cancer. 18(128)2019.PubMed/NCBI View Article : Google Scholar | |
|
Yáñez L, Sánchez-Escamilla M and Perales MA: CAR T cell toxicity: Current management and future directions. HemaSphere. 3(e186)2019.PubMed/NCBI View Article : Google Scholar | |
|
Ma CC, Wang ZL, Xu T, He ZY and Wei YQ: The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 40(107502)2020.PubMed/NCBI View Article : Google Scholar | |
|
Mullard A: FDA approves first CAR T therapy. Nat Rev Drug Discov. 16(669)2017.PubMed/NCBI View Article : Google Scholar | |
|
No authors listed. FDA approves second CAR T-cell therapy. Cancer Discov. 8:5–6. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Huang X and Yang Y: Driving an improved CAR for cancer immunotherapy. J Clin Invest. 126:2795–2798. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong JF, Zhang C, et al: Recent advances in CAR-T cell engineering. J Hematol Oncol. 13(86)2020.PubMed/NCBI View Article : Google Scholar | |
|
Jackson HJ, Rafiq S and Brentjens RJ: Driving CAR T-cells forward. Nat Rev Clin Oncol. 13:370–383. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Depil S, Duchateau P, Grupp SA, Mufti G and Poirot L: ‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges. Nat Rev Drug Discov. 19:185–199. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Schmidts A and Maus MV: Making CAR T cells a solid option for solid tumors. Front Immunol. 9(2593)2018.PubMed/NCBI View Article : Google Scholar | |
|
Chmielewski M and Abken H: TRUCKs: The fourth generation of CARs. Expert Opin Biol Ther. 15:1145–1154. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, Yang X, Sun J, Li Z, Han WD, et al: Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther. 4(35)2019.PubMed/NCBI View Article : Google Scholar | |
|
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, et al: JULIET Investigators: Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 380:45–56. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Yamada S, Kaneko MK, Sayama Y, Asano T, Sano M, Yanaka M, Nakamura T, Okamoto S, Handa S, Komatsu Y, et al: Development of novel mouse monoclonal antibodies against human CD19. Monoclon Antib Immunodiagn Immunother. 39:45–50. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Schubert ML, Hückelhoven A, Hoffmann JM, Schmitt A, Wuchter P, Sellner L, Hofmann S, Ho AD, Dreger P and Schmitt M: Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of stem cell transplantation. Hum Gene Ther. 27:758–771. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Iovino L and Shadman M: Novel therapies in chronic lymphocytic leukemia: A rapidly changing landscape. Curr Treat Options Oncol. 21(24)2020.PubMed/NCBI View Article : Google Scholar | |
|
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 7(303ra139)2015.PubMed/NCBI View Article : Google Scholar | |
|
Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al: CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 24:20–28. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Liu J, Tan X, Ma YY, Liu Y, Gao L, Gao L, Kong P, Peng XG, Zhang X and Zhang C: Study on the prognostic value of aberrant antigen in patients with acute B lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 19:e349–e358. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, Hilbert DM and LaFleur DW: Chimeric antigen receptors incorporating D domains targeting CD123 direct potent mono- and bi-specific antitumor activity of T cells. Mol Ther. 27:1262–1274. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Borot F, Wang H, Ma Y, Jafarov T, Raza A, Ali AM and Mukherjee S: Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc Natl Acad Sci USA. 116:11978–11987. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, Xu J, Zhuang Y, Zhang W, Weng XQ, et al: Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA. 116:9543–9551. 2019.PubMed/NCBI View Article : Google Scholar | |
|
D'Agostino M and Raje N: Anti-BCMA CAR T-cell therapy in multiple myeloma: Can we do better? Leukemia. 34:21–34. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, et al: T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 36:2267–2280. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Morandi F, Horenstein AL, Costa F, Giuliani N, Pistoia V and Malavasi F: CD38: A target for immunotherapeutic approaches in multiple myeloma. Front Immunol. 9(2722)2018.PubMed/NCBI View Article : Google Scholar | |
|
Vasuthasawat A, Yoo EM, Trinh KR, Lichtenstein A, Timmerman JM and Morrison SL: Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma. MAbs. 8:1386–1397. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Sun M, Shi H, Liu C, Liu J, Liu X and Sun Y: Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast Cancer Res. 16(R61)2014.PubMed/NCBI View Article : Google Scholar | |
|
Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, et al: Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res. 20:6418–6428. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, Su L, Wu X, Zhou J, Mackay S, et al: Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology. 158:2250–2265.e20. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z and Jiang H: Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J Immunol. 203:198–207. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wei X, Lai Y, Li J, Qin L, Xu Y, Zhao R, Li B, Lin S, Wang S, Wu Q, et al: PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. OncoImmunology. 6(e1284722)2017.PubMed/NCBI View Article : Google Scholar | |
|
Sotoudeh M, Shirvani SI, Merat S, Ahmadbeigi N and Naderi M: MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. J Cell Biochem. 120:5010–5017. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Zeng C, Cheng J, Li T, Huang J, Li C, Jiang L, Wang J, Chen L, Mao X, Zhu L, et al: Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Cytotherapy. 22:166–171. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhu H, You Y, Shen Z and Shi L: EGFRvIII-CAR-T cells with PD-1 knockout have improved anti-glioma activity. Pathol Oncol Res. 26:2135–2141. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Zhang BL, Li D, Gong YL, Huang Y, Qin DY, Jiang L, Liang X, Yang X, Gou HF, Wang YS, et al: Preclinical evaluation of chimeric antigen receptor-modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer. Hum Gene Ther. 30:402–412. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Liu K, Song G, Zhang X, Li Q, Zhao Y, Zhou Y, Xiong R, Hu X, Tang Z and Feng G: PTK7 is a novel oncogenic target for esophageal squamous cell carcinoma. World J Surg Oncol. 15(105)2017.PubMed/NCBI View Article : Google Scholar | |
|
Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, Jaimes EA, Perales MA and Sathick J: Acute kidney injury after CAR-T cell therapy: Low incidence and rapid recovery. Biol Blood Marrow Transplant. 26:1071–1076. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Aldoss I, Khaled SK, Budde E and Stein AS: Cytokine release syndrome with the novel treatments of acute lymphoblastic leukemia: Pathophysiology, prevention, and treatment. Curr Oncol Rep. 21(4)2019.PubMed/NCBI View Article : Google Scholar | |
|
Riegler LL, Jones GP and Lee DW: Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 15:323–335. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B and von Bergwelt-Baildon MS: Cytokine release syndrome. J Immunother Cancer. 6(56)2018.PubMed/NCBI View Article : Google Scholar | |
|
Chou CK and Turtle CJ: Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert Opin Biol Ther. 20:653–664. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Thakar MS, Kearl TJ and Malarkannan S: Controlling cytokine release syndrome to harness the full potential of CAR-based cellular therapy. Front Oncol. 9(1529)2020.PubMed/NCBI View Article : Google Scholar | |
|
Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, et al: Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 74:3099–3108. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Liu D and Zhao J: Cytokine release syndrome: Grading, modeling, and new therapy. J Hematol Oncol. 11(121)2018.PubMed/NCBI View Article : Google Scholar | |
|
Gödel P, Shimabukuro-Vornhagen A and von Bergwelt-Baildon M: Understanding cytokine release syndrome. Intensive Care Med. 44:371–373. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Acharya UH, Dhawale T, Yun S, Jacobson CA, Chavez JC, Ramos JD, Appelbaum J and Maloney DG: Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Rev Hematol. 12:195–205. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Gauthier J, Hirayama AV, Purushe J, Hay KA, Lymp J, Li DH, Yeung CCS, Sheih A, Pender BS, Hawkins RM, et al: Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood. 135:1650–1660. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Tu S, Zhou X, Guo Z, Huang R, Yue C, He Y, Li M, Chen Y, Liu Y, Chang LJ, et al: CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma. Front Oncol. 9(1350)2019.PubMed/NCBI View Article : Google Scholar | |
|
Shen D, Song H, Xu X, Xu W, Wang D, Liang J, Fang M, Liao C, Chen X, Li S, et al: Chimeric antigen receptor T cell therapy can be administered safely under the real-time monitoring of Th1/Th2 cytokine pattern using the cytometric bead array technology for relapsed and refractory acute lymphoblastic leukemia in children. Pediatr Hematol Oncol. 37:288–299. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cornillon J, Hadhoum N, Roth-Guepin G, Quessar A, Platon L, Ouachée-Chardin M, Nicolas-Virelizier E, Naudin J, Moreau AS, Masouridi-Levrat S, et al: Management of CAR-T cell-related encephalopathy syndrome in adult and pediatric patients: Recommendations of the French Society of Bone Marrow transplantation and cellular Therapy (SFGM-TC). Bull Cancer. 107:S12–S17. 2020.PubMed/NCBI View Article : Google Scholar : (In French). | |
|
Kennedy LB and Salama AKS: A review of cancer immunotherapy toxicity. CA Cancer J Clin. 70:86–104. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, et al: Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of Ibrutinib. J Clin Oncol. 35:3010–3020. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, et al: Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 133:2212–2221. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, et al: Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8:958–971. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet. 385:517–528. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Oved JH, Barrett DM and Teachey DT: Cellular therapy: Immune-related complications. Immunol Rev. 290:114–126. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Gupta A and Moore JA: Tumor lysis syndrome. JAMA Oncol. 4(895)2018.PubMed/NCBI View Article : Google Scholar | |
|
Feldmann A, Arndt C, Koristka S, Berndt N, Bergmann R and Bachmann MP: Conventional CARs versus modular CARs. Cancer Immunol Immunother. 68:1713–1719. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Neelapu SS: Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 37 (Suppl 1):48–52. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Xia AL, Wang XC, Lu YJ, Lu XJ and Sun B: Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: Challenges and opportunities. Oncotarget. 8:90521–90531. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G Jr, Hong DS, Shpall EJ and Kebriaei P: Chimeric antigen receptor therapy: How are we driving in solid tumors? Biol Blood Marrow Transplant. 26:1759–1769. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, et al: Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 21:3149–3159. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y and Tamada K: IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 36:346–351. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Alanio C, Barreira da Silva R, Michonneau D, Bousso P, Ingersoll MA and Albert ML: CXCR3/CXCL10 Axis Shapes Tissue Distribution of Memory Phenotype CD8+ T Cells in Nonimmunized Mice. J Immunol. 200:139–146. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Liu L, Bi E, Ma X, Xiong W, Qian J, Ye L, Su P, Wang Q, Xiao L, Yang M, et al: Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9. Nat Commun. 11(5902)2020.PubMed/NCBI View Article : Google Scholar | |
|
Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S and Paulos CM: CAR T Cells in solid tumors: Blueprints for building effective therapies. Front Immunol. 9(1740)2018.PubMed/NCBI View Article : Google Scholar | |
|
Morgan MA and Schambach A: Engineering CAR-T cells for improved function against solid tumors. Front Immunol. 9(2493)2018.PubMed/NCBI View Article : Google Scholar | |
|
Yu S, Yi M, Qin S and Wu K: Next generation chimeric antigen receptor T cells: Safety strategies to overcome toxicity. Mol Cancer. 18(125)2019.PubMed/NCBI View Article : Google Scholar | |
|
Akbari P, Huijbers EJM, Themeli M, Griffioen AW and van Beijnum JR: The tumor vasculature an attractive CAR T cell target in solid tumors. Angiogenesis. 22:473–475. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Gargett T and Brown MP: The inducible caspase-9 suicide gene system as a ‘safety switch’ to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 5(235)2014.PubMed/NCBI View Article : Google Scholar | |
|
Kloss CC, Condomines M, Cartellieri M, Bachmann M and Sadelain M: Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 31:71–75. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Liu D, Zhao J and Song Y: Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol. 12(69)2019.PubMed/NCBI View Article : Google Scholar |
